Biohaven Pharmaceutical Holding Company Ltd. [NYSE: BHVN] jumped around 3.55 points on Friday, while shares priced at $79.15 at the close of the session, up 4.70%. The company report on May 14, 2021 that Biohaven’s Nurtec® ODT Signs as Primary Partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program.
Biohaven Pharmaceuticals (NYSE:BHVN) announced that Nurtec® ODT (rimegepant) will be the primary partner for the Rick Ware Racing No. 51 NTT IndyCar Series program. Nurtec ODT’s vibrant colors have already been on display on the No. 51 Honda for the season opener at Barber Motorsports Park and the double-header weekend at Texas Motor Speedway. Nurtec ODT is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT) designed for rapid onset of action.
“We are grateful for the continued support of our partners at Biohaven and Nurtec ODT,” commented team owner Rick Ware. “Nurtec ODT is one, if not the only, partner in both the NASCAR Cup Series and NTT IndyCar Series, whose primary colors are on board every weekend. We have created some great programs for the 2021 season, and I’m excited to expand the program to cover the IndyCar Series full-time as well.”.
Biohaven Pharmaceutical Holding Company Ltd. stock is now -7.65% down from its year-to-date (YTD) trading value. BHVN Stock saw the intraday high of $79.83 and lowest of $75.38 per share. The company’s 52-week high price is 100.77, which means current price is +26.50% above from all time high which was touched on 01/27/21.
Compared to the average trading volume of 608.17K shares, BHVN reached a trading volume of 1004047 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Biohaven Pharmaceutical Holding Company Ltd. [BHVN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BHVN shares is $99.91 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BHVN stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Biohaven Pharmaceutical Holding Company Ltd. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 11, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 15, 2020, representing the official price target for Biohaven Pharmaceutical Holding Company Ltd. stock. Previously, the target price had yet another raise to $45, while Cowen analysts kept a Outperform rating on BHVN stock.
The Average True Range (ATR) for Biohaven Pharmaceutical Holding Company Ltd. is set at 3.43, with the Price to Sales ratio for BHVN stock in the period of the last 12 months amounting to 46.28.
How has BHVN stock performed recently?
Biohaven Pharmaceutical Holding Company Ltd. [BHVN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.31. With this latest performance, BHVN shares gained by 5.24% in over the last four-week period, additionally sinking by -19.43% over the last 6 months – not to mention a rise of 51.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BHVN stock in for the last two-week period is set at 64.16, with the RSI for the last a single of trading hit 71.79, and the three-weeks RSI is set at 59.01 for Biohaven Pharmaceutical Holding Company Ltd. [BHVN]. The present Moving Average for the last 50 days of trading for this stock 71.99, while it was recorded at 73.77 for the last single week of trading, and 76.92 for the last 200 days.
Biohaven Pharmaceutical Holding Company Ltd. [BHVN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Biohaven Pharmaceutical Holding Company Ltd. [BHVN] shares currently have an operating margin of -1014.33 and a Gross Margin at +72.19. Biohaven Pharmaceutical Holding Company Ltd.’s Net Margin is presently recorded at -1205.14.
Return on Total Capital for BHVN is now -185.55, given the latest momentum, and Return on Invested Capital for the company is -269.69. Additionally, BHVN Total Debt to Total Capital is recorded at 198.30, with Total Debt to Total Assets ending up at 114.63.
Reflecting on the efficiency of the workforce at the company, Biohaven Pharmaceutical Holding Company Ltd. [BHVN] managed to generate an average of -$929,450 per employee. Receivables Turnover for the company is 1.06 with a Total Asset Turnover recorded at a value of 0.12.Biohaven Pharmaceutical Holding Company Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.30.
Earnings analysis for Biohaven Pharmaceutical Holding Company Ltd. [BHVN]
With the latest financial reports released by the company, Biohaven Pharmaceutical Holding Company Ltd. posted -3.08/share EPS, while the average EPS was predicted by analysts to be reported at -2.61/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -18.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BHVN.
Insider trade positions for Biohaven Pharmaceutical Holding Company Ltd. [BHVN]
There are presently around $4,866 million, or 91.25% of BHVN stock, in the hands of institutional investors. The top three institutional holders of BHVN stocks are: CAPITAL INTERNATIONAL INVESTORS with ownership of 5,578,232, which is approximately 4.638% of the company’s market cap and around 4.00% of the total institutional ownership; CAPITAL WORLD INVESTORS, holding 4,739,936 shares of the stock with an approximate value of $375.17 million in BHVN stocks shares; and BLACKROCK INC., currently with $299.47 million in BHVN stock with ownership of nearly 7.336% of the company’s market capitalization.
Positions in Biohaven Pharmaceutical Holding Company Ltd. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 121 institutional holders increased their position in Biohaven Pharmaceutical Holding Company Ltd. [NYSE:BHVN] by around 9,088,349 shares. Additionally, 133 investors decreased positions by around 4,660,725 shares, while 18 investors held positions by with 47,729,033 shares. The mentioned changes placed institutional holdings at 61,478,107 shares, according to the latest SEC report filing. BHVN stock had 36 new institutional investments in for a total of 2,534,828 shares, while 47 institutional investors sold positions of 1,179,678 shares during the same period.